How is a general drug? Wikipedia gives the following definition: "Drug without brands (pl. drugs without brands, briefly: Generics) is a narcotic which is generated and is distributed without trade name. General must contain the same active ingredients like the original formulation. In most cases it is looked as bioequivalent of the trade name copy concerning pharmacokinetic and pharmacodynamic qualities. By the enlargement, therefore, as one accepts, are identical generics in the dose, the strength, the way from government, security, effect, and deliberate use." Does a general drug differ from a trade name narcotic? Not a lot, really. But there is a difference of course. To see the difference clearer, we have made a table: Do you click here Why the general pills are less expensive than the trade name? The principal reason for the diminished price of general medicaments is that the development of the runs of the drug without brands less costs and, therefore, a lower price can be offered and maintain still profitability. Manufacturers of drugs without brands are principal in the state to avoid the following three costs which take over trade name medicament societies: To wrong costs with the research and development of the narcotic; united costs, realisation approval receiving (i.e. security and effect of a narcotic proving); and market costs. First the costs of the narcotic discovery and, instead, back of engineer available trade name narcotics do not take over universal manufacturer to permit to them, to manufacture bioequivalent versions. Secondly general manufacturers do not endure the load to prove rather the security and effect of the narcotics by clinical tests - general manufacturers must prove bioequivalancy of the drug without brands to the available narcotic. Thirdly these societies receive the big advantage of the marketing and the advertisement which enters into pushing the innovator's narcotic. The trade name narcotic must prove itself in the eyes of the consumer, general ones do not act. The narcotics which general manufacturers sell have been at the market since normally decade or more and do not need additional advertisement. For same reason general manufacturers also do not give away example tins to promote her products. The important research, development and market costs which are taken over from the big pharmaceutical societies in introducing a new narcotic to the market are often cited as the reason for the high costs by new agents - they would like to attain these costs again, before the patent runs off.
Thursday, December 17, 2009
Popular Ed Products
How is a general drug? Wikipedia gives the following definition: "Drug without brands (pl. drugs without brands, briefly: Generics) is a narcotic which is generated and is distributed without trade name. General must contain the same active ingredients like the original formulation. In most cases it is looked as bioequivalent of the trade name copy concerning pharmacokinetic and pharmacodynamic qualities. By the enlargement, therefore, as one accepts, are identical generics in the dose, the strength, the way from government, security, effect, and deliberate use." Does a general drug differ from a trade name narcotic? Not a lot, really. But there is a difference of course. To see the difference clearer, we have made a table: Do you click here Why the general pills are less expensive than the trade name? The principal reason for the diminished price of general medicaments is that the development of the runs of the drug without brands less costs and, therefore, a lower price can be offered and maintain still profitability. Manufacturers of drugs without brands are principal in the state to avoid the following three costs which take over trade name medicament societies: To wrong costs with the research and development of the narcotic; united costs, realisation approval receiving (i.e. security and effect of a narcotic proving); and market costs. First the costs of the narcotic discovery and, instead, back of engineer available trade name narcotics do not take over universal manufacturer to permit to them, to manufacture bioequivalent versions. Secondly general manufacturers do not endure the load to prove rather the security and effect of the narcotics by clinical tests - general manufacturers must prove bioequivalancy of the drug without brands to the available narcotic. Thirdly these societies receive the big advantage of the marketing and the advertisement which enters into pushing the innovator's narcotic. The trade name narcotic must prove itself in the eyes of the consumer, general ones do not act. The narcotics which general manufacturers sell have been at the market since normally decade or more and do not need additional advertisement. For same reason general manufacturers also do not give away example tins to promote her products. The important research, development and market costs which are taken over from the big pharmaceutical societies in introducing a new narcotic to the market are often cited as the reason for the high costs by new agents - they would like to attain these costs again, before the patent runs off.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment